Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.

Biotech R&D: Alnylam vs. Amicus - A Decade of Investment

__timestampAlnylam Pharmaceuticals, Inc.Amicus Therapeutics, Inc.
Wednesday, January 1, 201419024900047624000
Thursday, January 1, 201527649500076943000
Friday, January 1, 2016382392000104793000
Sunday, January 1, 2017390635000149310000
Monday, January 1, 2018505420000270902000
Tuesday, January 1, 2019655114000286378000
Wednesday, January 1, 2020654819000308443000
Friday, January 1, 2021792156000272049000
Saturday, January 1, 2022883015000276677000
Sunday, January 1, 20231004415000152381000
Monday, January 1, 20241126232000
Loading chart...

Unlocking the unknown

A Decade of Innovation: R&D Investments in Biotech

In the competitive world of biotechnology, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D spending.

Alnylam Pharmaceuticals, Inc.

Since 2014, Alnylam has consistently increased its R&D investments, peaking in 2023 with a staggering 430% increase from 2014. This commitment underscores their dedication to pioneering RNA interference therapeutics.

Amicus Therapeutics, Inc.

Conversely, Amicus Therapeutics has shown a more modest growth in R&D spending, with a 220% increase over the same period. Their focus remains on developing therapies for rare diseases, reflecting a steady yet strategic approach.

These investment trends highlight the dynamic nature of biotech innovation, where strategic R&D spending can significantly influence a company's trajectory and impact on healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025